Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
AAPS PharmSciTech. 2018 May;19(4):1730-1743. doi: 10.1208/s12249-018-0985-4. Epub 2018 Mar 22.
The aim of present study is to formulate diphenhydramine nasal nano-emulgels, having lipophilic nano-sized interior droplets, with better penetration for targeted controlled delivery to mucous membrane. Different diphenhydramine (DPH) nasal nano-emulgels were developed having propylene glycol and olive oil (as permeation enhancers) by using RSM for optimization and then evaluated for physico-chemical characteristics and thermal stability. In-vitro drug release through cellophane membrane was conducted and results were analyzed statistically. Further, gelation, mucoadhesive stress, and ex-vivo and histopathological studies were performed on optimized formulation by using goat nasal membrane. Among all formulations, E2 showed maximum DPH release at higher concentration olive oil (4%) and lower concentration propylene glycol (PG) (25%) within 4 h. All formulations have followed first-order kinetics and drug release mechanism was Fickian diffusion. Analysis of variance (ANOVA) and multiple linear regression analysis (MLRA) were used to compare results among formulations and 3D surface plots were constructed also. Optimized formulation showed immediate prolong gelation in artificial nasal mucosa and excellent mucoadhesive property (72.5 ± 1.5 dynes/cm). Approximately 97.1% optimized formulation was permeated through membrane within 4 h, having a high flux rate (33.19 ± 0.897 μg/cm/min) with diffusion coefficient (0.000786 ± 4.56 × 10 cm/min) while drug contents remained on mucosal membrane for 24 h. Histopathologically, change on intra-mucosal surface of excised membrane was observed due to passage of drug through it. In summary, combination of PG and olive oil in nasal DPH nano-emulgel can be utilized successfully for targeted controlled delivery. The optimized formulation has excellent permeability and prolonged residence time on mucosal surface, which prove its good anti-histaminic activity in case of allergic rhinitis.
本研究的目的是制备具有亲脂性纳米内部液滴的盐酸苯海拉明鼻腔纳米乳凝胶,以更好地穿透粘膜,实现靶向控制递药。使用响应面法(RSM)对不同的盐酸苯海拉明(DPH)鼻用纳米乳凝胶进行了优化,考察了处方的理化性质和热稳定性。通过纤维素膜进行了体外药物释放研究,并对结果进行了统计学分析。进一步,使用山羊鼻黏膜对优化后的配方进行了凝胶化、粘膜粘附力、离体和组织病理学研究。在所有配方中,E2 在较高浓度橄榄油(4%)和较低浓度丙二醇(PG)(25%)下,在 4 小时内显示出最大的 DPH 释放。所有配方均符合一级动力学,药物释放机制为菲克扩散。方差分析(ANOVA)和多元线性回归分析(MLRA)用于比较配方之间的结果,还构建了 3D 表面图。优化后的配方在人工鼻黏膜中立即延长了凝胶时间,具有良好的粘膜粘附性(72.5±1.5 dynes/cm)。大约 97.1%的优化配方在 4 小时内透过膜,通量率高(33.19±0.897μg/cm/min),扩散系数(0.000786±4.56×10 cm/min),药物含量在 24 小时内仍保留在粘膜上。组织病理学检查显示,由于药物通过它,切除膜的粘膜内表面发生了变化。总之,PG 和橄榄油在鼻用 DPH 纳米乳凝胶中的结合可成功用于靶向控制递药。优化后的配方具有良好的渗透性和在粘膜表面的延长滞留时间,证明其在治疗过敏性鼻炎方面具有良好的抗组胺活性。